Xconomy

OCTOBER 28, 2016

Two “triple” combination regimens for CF , which are meant to expand the reach of its CF drugs, will begin Phase 2 trials by the end of the year, and two additional new CF drugs will start clinical testing in 2017. THIS WEEK IN DRUG PRICING…. —A coalition of investors pressed drug makers to justify price increases.

Pricing 40

Pricing Conference News Study 40

Xconomy

MARCH 8, 2019

In early 2017, Scott Gottlieb was considered the most moderate of the potential candidates to head the Food and Drug Administration, which is the most powerful regulator of medical products in the world. It wasn’t a high bar to clear. Still, Gottlieb had spent time in the George W. His potential financial conflicts, combined.

Report 77

Report Product San Diego Pricing 77

Xconomy

MARCH 5, 2019

He leaves a record of health and medical regulation that was more active than critics who spoke out against his nomination in early 2017 might have expected. Two months after insisting on Twitter that he wasn’t going anywhere , Food and Drug Administration Commissioner Scott Gottlieb announced his resignation today.

News 87

News Course Activity San Diego 87

Xconomy

OCTOBER 7, 2016

The funding could be as much as $100 million, and the first grants will be announced in 2017. PRICE FIGHTS. With some caveats, ICER recommended lower prices. . —The U.S. THE ENVELOPE, PLEASE. —The 2016 Nobel Prize for Physiology or Medicine went to Yoshinori Ohsumi of the Tokyo Institute of Technology.

Technical Review 77

Technical Review Study Layoffs San Diego 77

Xconomy

JANUARY 27, 2017

Jounce Therapeutics has gone ahead of its projections and raised roughly $102 million in an IPO, continuing an early, yet successful trend for biotechs trying to go public in 2017. Jounce also priced above the $13 to $15 per share range it had set. It will start trading on the Nasdaq this morning under the symbol “JNCE.”

Pricing 40

Pricing San Diego Company Companies 40

Xconomy

DECEMBER 23, 2016

The biggest issues of 2016 are also the biggest questions of 2017: What do the Trump administration and Republican-led Congress have in store for federal health initiatives, laws, and agency budgets? Will government and public pressure force change on drug prices? Or will drug makers and.

Pricing 40

Pricing San Diego Blogging 40

Xconomy

NOVEMBER 11, 2016

Drug company stocks got a boost with the defeat of Hillary Clinton, a vocal critic of drug prices. Will he take a softer stance on drug prices? But her near doubling of Trump (62 to 33 percent) didn’t translate into support for drug price controls. Now, the U.S. healthcare sector will try to figure out what it all means.

Patents 87

Patents Study Pricing Research 87

Xconomy

JANUARY 27, 2017

And a group of biotechs led by Jounce Therapeutics were the first to test the IPO market in 2017. A flurry of deals took place, headlined by Johnson & Johnson’s $30 billion gamble on Swiss firm Actelion. Meanwhile in Washington, President Donald Trump spent much of his first week signing executive orders on a variety of.

News 40

News Study Marketing Anthem 40

Xconomy

AUGUST 26, 2016

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. It was the tweet heard around the biotech world, again.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

AUGUST 19, 2016

Everyone is waiting until 2017, when huge studies of the drugs’ ability to prevent heart attacks and strokes start to provide data. Data from the other three trials should come in late 2016 or early 2017.

Technical Review 40

Technical Review Patents .Net Study 40

Xconomy

AUGUST 12, 2016

The new company, expected to launch in 2017, will trade on the Nasdaq under the symbol “BIVV” when the split is complete. —This week’s gene therapy news: MIT Technology Review reported that Strimvelis, the gene therapy recently approved in Europe and given a $665,000 price tag, has a money-back guarantee if it doesn’t work.

Google 40

Google Technical Review News Research 40

Xconomy

JANUARY 5, 2018

Hopefully a lot less hatred, greed, stupidity, and angst than 2017. Two other big questions we raised immediately became topics of conversation this week, thanks to Spark Therapeutics, which set the price for its gene therapy—the first ever approved in the U.S.—at Welcome to the new year. What will it bring?

Pricing 55

Pricing News Develop Development 55